The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Open accessAbstract
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
Self-citationGuillemot, F., Lo, L.-C., Johnson, J. E., Auerbach, A., Anderson, D. J., & Joyner, A. L. (1993) · Cell · doi:10.1016/0092-8674(93)90381-y · Cited by 1,033
Fehon, R. G., Kooh, P. J., Rebay, I., Regan, C. L., Xu, T., Muskavitch, M. A. T., & Artavanis-Tsakonas, S. (1990) · Cell · doi:10.1016/0092-8674(90)90534-l · Cited by 673
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534
A Genomics-Based Classification of Human Lung Tumors
The Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM) (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006802 · Cited by 511
An achaete-scute homologue essential for neuroendocrine differentiation in the lung
Borges, M., Linnoila, R. I., van de Velde, H. J. K., Chen, H., Nelkin, B. D., Mabry, M., Baylin, S. B., & Ball, D. W. (1997) · Nature · doi:10.1038/386852a0 · Cited by 454
Reynolds, S. D., Giangreco, A., Power, J. H. T., & Stripp, B. R. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64727-x · Cited by 447
Cited by
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Role of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationNotch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Small-cell lung cancer: what we know, what we need to know and the path forward
Gazdar, A. F., Bunn, P. A., & Minna, J. D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.87 · Cited by 904
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Antibody–drug conjugates for cancer therapy
Thomas, A., Teicher, B. A., & Hassan, R. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30030-4 · Cited by 606
Mollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.005 · Cited by 588
Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Self-citationLineage plasticity in cancer: a shared pathway of therapeutic resistance
Quintanal-Villalonga, Á., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T., & Rudin, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0340-z · Cited by 572
Self-citationBaine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.009 · Cited by 522
Self-citationIreland, A. S., Micinski, A. M., Kastner, D. W., Guo, B., Wait, S. J., Spainhower, K. B., Conley, C. C., Chen, O. S., Guthrie, M. R., Soltero, D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.001 · Cited by 508
Borromeo, M. D., Savage, T. K., Kollipara, R. K., He, M., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 503
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Self-citationImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz-Cordero, R., & Devine, W. P. (2020) · Surgical Pathology Clinics · doi:10.1016/j.path.2019.11.002 · Cited by 448
Chan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Self-citationEmerging therapies for small cell lung cancer
Yang, S., Zhang, Z., & Wang, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0736-3 · Cited by 407
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F., Maas, L., Müller, C., Dahmen, I., Delhomme, T. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03099-x · Cited by 377
Self-citationPaz-Ares, L., Champiat, S., Lai, W. V., Izumi, H., Govindan, R., Boyer, M., Hummel, H.-D., Borghaei, H., Johnson, M. L., Steeghs, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02823 · Cited by 336
Self-citationMorgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
Self-citationAntibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 314
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Lambert, J. M., & Morris, C. Q. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0519-6 · Cited by 304
Blackhall, F., Jao, K., Greillier, L., Cho, B. C., Penkov, K., Reguart, N., Majem, M., Nackaerts, K., Syrigos, K., Hansen, K., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.009 · Cited by 279
Dasari, A., Mehta, K., Byers, L. A., Sorbye, H., & Yao, J. C. (2018) · Cancer · doi:10.1002/cncr.31124 · Cited by 277
Targeting Notch in oncology: the path forward
Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00091-3 · Cited by 270
Zhang, W., Girard, L., Zhang, Y.-A., Haruki, T., Papari-Zareei, M., Stastny, V., Ghayee, H. K., Pacak, K., Oliver, T. G., Minna, J. D., et al. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.02 · Cited by 263
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Mantaj, J., Jackson, P. J. M., Rahman, K. M., & Thurston, D. E. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201510610 · Cited by 262
Giffin, M. J., Cooke, K., Lobenhofer, E. K., Estrada, J., Zhan, J., Deegen, P., Thomas, M., Murawsky, C. M., Werner, J., Liu, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2845 · Cited by 258
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Puca, L., Gavyert, K., Sailer, V., Conteduca, V., Dardenne, E., Sigouros, M., Isse, K., Kearney, M., Vosoughi, A., Fernandez, L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0891 · Cited by 214
Self-citationAntibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
Hartley, J. A. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1776255 · Cited by 109
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00214-y · Cited by 80
von Arx, C., Capozzi, M., López-Jiménez, E., Ottaiano, A., Tatangelo, F., Di Mauro, A., Nasti, G., Tornesello, M. L., & Tafuto, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091277 · Cited by 24
Metadata
- Authors
- Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., Liu, D., Lopez-Molina, J., Milton, M., Park, A., Pysz, M. A., Shao, H., Slingerland, B., Torgov, M., Williams, S. A., Foord, O., Howard, P., Jassem, J., Badzio, A., Czapiewski, P., Harpole, D. H., Dowlati, A., Massion, P. P., Travis, W. D., Pietanza, M. C., Poirier, J. T., Rudin, C. M., Stull, R. A., & Dylla, S. J.
- Venue
- Science Translational Medicine
- Published
- 2015-08-26
- Volume
- 7
- Issue
- 302
- Pages
- 302ra136-302ra136
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W1822869875
- Cited by
- 600
- References
- 49
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.